In CRC mouse models, it was shown that TGF-β elevation in the tumor microenvironment confers resistance to anti-PD-1 therapy via inhibition of T-cell infiltration and decreased levels of type 1 T-helper cell phenotype (94). This evidence concerns the gene TGFB1 and neoplasm.